Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.68 |
| ▸ | TMPRSS6 | Q8IU80 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | F2 | P00734 | 4/20 | 0.48 |
| ▸ | F10 | P00742 | 2/20 | 0.48 |
| ▸ | F12 | P00748 | 1/20 | 0.48 |
| ▸ | F7 | P08709 | 1/20 | 0.48 |
| ▸ | F3 | P13726 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.47 |
| ▸ | PRSS2 | P07478 | 4/20 | 0.47 |
| ▸ | PRSS3 | P35030 | 4/20 | 0.47 |
| ▸ | C1S | P09871 | 3/20 | 0.47 |
| ▸ | PLG | P00747 | 1/20 | 0.47 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.47 |
| ▸ | WDR5 | P61964 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8556017 | 0.93 | TSHR (0.58) | TSHRHSD17B10TMPRSS6MAPTF2 | |
| SCHEMBL20853419 | 0.85 | TSHR (0.75) | TSHRHSD17B10MAPTF2PRSS1 | |
| SCHEMBL8554901 | 0.84 | MAPT (0.54) | TSHRHSD17B10MAPTF2F10 | |
| SCHEMBL7427012 | 0.84 | TMPRSS6 (0.51) | TSHRHSD17B10TMPRSS6F2F10 | |
| Phenylmethanesulfonic Acid SCHEMBL7148383 | 0.83 | F2 (0.52) | TSHRHSD17B10TMPRSS6F2F10 | |
| SCHEMBL8556051 | 0.83 | PRSS1 (0.59) | TSHRHSD17B10F2F10F12 | |
| SCHEMBL11827401 | 0.81 | TSHR (1.00) | TSHRHSD17B10MAPTKMT2ACA1 | |
| SCHEMBL11759551 | 0.79 | TSHR (0.71) | TSHRHSD17B10MAPTCA1CA2 | |
| Phenylmethylsulfonylfluoride SCHEMBL3497005 | 0.78 | PRSS1 (0.66) | TMPRSS6F2F10F12F7 | |
| SCHEMBL2981657 | 0.78 | TSHR (0.75) | TSHRHSD17B10MAPTKMT2ACA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190307737-A1 | NOVEL PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2019-10-10 | — | — | US | disclosed |
| US-20190307737-A1 | NOVEL PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2019-10-10 | — | — | US | disclosed |
| EP-3227282-B1 | NOVEL PIPERIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2019-04-03 | — | — | EP | disclosed |
| EP-3227282-B1 | NOVEL PIPERIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2019-04-03 | — | — | EP | disclosed |
| US-10172843-B2 | Piperidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-10172843-B2 | Piperidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-20170266175-A1 | NOVEL PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2017-09-21 | — | — | US | disclosed |
| US-20170266175-A1 | NOVEL PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2017-09-21 | — | — | US | disclosed |
| US-20170266175-A1 | NOVEL PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2017-09-21 | — | — | US | disclosed |
| WO-2016087352-A1 | NOVEL PIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2016-06-09 | — | — | WO | disclosed |
| US-6114328-A | ANTICOAGULANTS; BLOOD DISORDERS | DUPONT PHARMACEUTICALS COMPANY (US) | 2000-09-05 | — | — | US | disclosed |
| US-5849736-A | Isoxazoline and isoxazole fibrinogen receptor antagonists | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190307737-A1 | NOVEL PIPERIDINE DERIVATIVES | ADORA1, ADRA1D, ADORA2B | TSHR 2069/4885HSD17B10 3503/4885TMPRSS6 2868/4885 |
| US-20170266175-A1 | NOVEL PIPERIDINE DERIVATIVES | ADORA1, ADRA1D, ADORA2B | TSHR 2069/4885HSD17B10 3503/4885TMPRSS6 2868/4885 |
| US-10172843-B2 | Piperidine derivatives | ADRA1D, ADORA1, ADRA1A | TSHR 1494/4885HSD17B10 3686/4885TMPRSS6 3204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.